Affinity Asset Advisors LLC Buys Shares of 130,000 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Affinity Asset Advisors LLC purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 130,000 shares of the company's stock, valued at approximately $5,018,000. Affinity Asset Advisors LLC owned 0.22% of Protagonist Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PTGX. FNY Investment Advisers LLC purchased a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at approximately $38,000. Covestor Ltd grew its position in shares of Protagonist Therapeutics by 5,200.0% during the 4th quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after buying an additional 1,612 shares in the last quarter. KBC Group NV increased its stake in shares of Protagonist Therapeutics by 54.4% during the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock valued at $81,000 after buying an additional 737 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after buying an additional 295 shares during the period. Finally, Cibc World Markets Corp bought a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at about $211,000. Institutional investors own 98.63% of the company's stock.

Analyst Upgrades and Downgrades

PTGX has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. BMO Capital Markets upped their price objective on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. BTIG Research set a $73.00 price objective on shares of Protagonist Therapeutics in a research note on Monday, March 3rd. Truist Financial lifted their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a report on Thursday, April 10th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $65.44.

Protagonist Therapeutics Trading Up 1.0 %

NASDAQ PTGX traded up $0.48 during trading hours on Friday, reaching $46.28. The company had a trading volume of 517,389 shares, compared to its average volume of 845,844. The stock has a market capitalization of $2.84 billion, a P/E ratio of 17.40 and a beta of 2.30. The stock has a 50-day moving average of $44.86 and a 200 day moving average of $42.80. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $2.07. The firm had revenue of $170.64 million during the quarter, compared to analysts' expectations of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of Protagonist Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total transaction of $204,606.62. Following the completion of the sale, the chief executive officer now directly owns 540,260 shares of the company's stock, valued at approximately $20,627,126.80. The trade was a 0.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William D. Waddill sold 4,000 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the sale, the director now owns 13,130 shares in the company, valued at approximately $712,302.50. This represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,776 shares of company stock valued at $3,585,010 in the last 90 days. Company insiders own 5.40% of the company's stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.